NASDAQ:NXGL NEXGEL Q2 2023 Earnings Report $2.63 +0.07 (+2.73%) As of 12:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings History NEXGEL EPS ResultsActual EPS-$0.12Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANEXGEL Revenue ResultsActual Revenue$1.17 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANEXGEL Announcement DetailsQuarterQ2 2023Date8/14/2023TimeN/AConference Call DateMonday, August 14, 2023Conference Call Time4:30PM ETUpcoming EarningsNEXGEL's Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by NEXGEL Q2 2023 Earnings Call TranscriptProvided by QuartrAugust 14, 2023 ShareLink copied to clipboard.There are 4 speakers on the call. Operator00:00:00Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to Nextel Incorporated's 2nd Quarter 2023 Earnings Conference Call. I will now turn the call over to Walter Pinto, Managing Director of KCSA Strategic Communications, for introductions. Please go ahead. Speaker 100:00:23Thank you, operator. Good afternoon, and welcome, everyone, to Nextel's Q2 2023 earnings conference call. I'm joined today by Adam Levy, Chief Executive Officer Adam Drabc, Chief Financial Officer of Nextel. Before we begin, I'd like to remind everyone that statements made during today's conference call may be deemed forward looking statements within the meaning of the Safe Harbor of the Private Securities Litigation Reform Act of 1995, and actual results may differ materially due to a variety of risks, uncertainties and other factors. For a detailed discussion of some of the ongoing risks and uncertainties in the company's business, I refer you to the press release issued this evening and filed with the SEC on Form 8 ks as well as the company's reports filed periodically with the SEC. Speaker 100:01:09The company disclaims any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by law. With that, it's my pleasure to turn the call over to Mr. Adam Levy. Adam, please go ahead. Speaker 200:01:26Thank you, Walter, and thank you everyone for joining us today to discuss our Q2 2023 financial and operating results. For the Q2 of 2023, we reported record revenue of $1,170,000 an increase of 108% year over year that exceeded our guidance. This substantial year over year growth reflects sales growth in both our contract manufacturing and branded consumer products. Our contract manufacturing line of business increased 174% year over year, mainly due to the full quarter contribution of our newly formed joint venture CG Converting and Packaging, as well as an increase from our existing core customers. On the branded consumer side, this was our best quarter ever, reflecting strong sales within the Amazon marketplace. Speaker 200:02:16New and existing direct to consumer branded products continued to perform well during the quarter, increasing sales by 44% year over year. Silverseal has become a hero product for us and continues to gain popularity and the reviews are very positive. This product is a unique hydrogel dressing for wounds and burns. These sterile silver patches are FDA cleared and have been clinically shown to kill 99% of staph MRSA and strep. They've also been shown to reduce scarring in wounds. Speaker 200:02:47Silverseal was a behind the counter hospital device for many years and our messaging of hospital grade product now available for home use has resonated well with consumers. In the coming months, we will be seeking to expand Silverseal's distribution into retail and other territories. We've already begun the process to obtain a CE mark as we have interest already from potential partners in Europe. For the Q2, we reported gross profit of 175,000 versus a gross loss of $57,000 in Q1 of 2023. The 2nd quarter included enhanced amounts of promotional materials, customer product samples and other marketing materials to support our new product line launches. Speaker 200:03:31We don't expect these costs to recur in the 3rd Q4. Therefore, we expect our margins to continue to improve in the second half of the year. Our net loss for the quarter was $695,000 down from $814,000 in the Q1 of this year. The improvement in the quarterly loss is attributable to our strong top line growth and the inclusion of a full quarter of CG Converting and Packaging. Our cash and cash equivalent balance, when you include marketable securities, decreased from $5,800,000 as of March 31, 2023 to $4,300,000 at June 30, 2023. Speaker 200:04:11The delta between our improved net loss during the quarter and the net cash decrease period over period was related to an increase in accounts receivables, increased prepaids and other current assets and capital equipment investments. First, the customers of CG Converting and Packaging require lengthier payment terms as their payment terms are closer to 90 days as compared to Nextel's customers who typically receive 30 day payment terms. Therefore, our accounts receivable increased during the quarter by $570,000 to $950,000 total. Prepaids and other current assets increased by $238,000 in the 2nd quarter to $366,000 In 2023, we eliminated the financing of our insurance policies and other higher interest items that we had historically financed, thereby saving the cost of the related interest expense. We also invested an additional $168,000 in property, plant and equipment at Nextel in anticipation of future increased customer demand. Speaker 200:05:16Taking into account the investments we made, we ended the quarter with $4,300,000 in cash, which continues to provide us with sufficient cash runway to operate and invest in accelerating our growth going forward. Our 2nd quarter results were our 1st full quarter with CG Converting and Packaging. We have already begun to realize the benefits of this joint venture. It has contributed materially to our top line growth and is accretive to the bottom line as well. These benefits will only increase once the planned expansion, installation and validation of the new equipment is complete. Speaker 200:05:51Our Q2 results did not include any sales for our new amblyopia patch due to supply chain delays. We have now received all of the materials and we'll be shipping our initial orders this month. We will have early results on adoption in Q3. More recently, in July, we announced a new strategic relationship with Eneta Health, a joint venture company for retail distribution and marketing services in North America. Now that we have fully vetted the audience for our leading products and have gained steady traction in the market, it is time to put these products on shelves. Speaker 200:06:25Enigma's leadership includes Joe Mignaka, an esteemed leader who has served in multiple executive roles, including CEO of Masaz Gandhi, President of Walgreens and President of Duane Reade. It also includes George Lant, a 30 year plus executive with experience in strategic food, drug brokerage sales and marketing. We are excited to leverage the expertise and market presence of Enigma Health's management team to expedite the delivery of our cutting edge hydrogel patches directly to consumers. Joe and George are experts and will be great partners for us. We are actively speaking with many leading retailers and expect to have more news on the progress of our rollout throughout the remainder of the year. Speaker 200:07:07Now halfway through Q3, we are pleased with the trending of our branded products. The sequential growth trend we saw in the first half of the year has continued into the current Q3. We had a very strong July and the 1st 2 weeks of August, and we see continued growth on all of our products on Amazon. We are also continuing to see good sales momentum in contract manufacturing. In closing, we believe in our ability to attract new customers to both Nextel and CG converting and packaging in the second half of twenty twenty three, and we believe that we are well positioned for long term growth. Speaker 200:07:42With that, I would like to turn the call over to our CFO, Adam Drabcic. Adam? Speaker 300:07:48Thank you, Adam. Today, I'll review financial highlights of our Q2 2023 results. For the Q2 of 2023, as Adam mentioned, revenue totaled $1,170,000 an increase of $606,000 or 108 percent, as compared to $561,000 in the Q2 of 2022. This growth was primarily due to sales growth in contract manufacturing of 174% and branded products of 44% year over year. On the branded consumer side, this was our best quarter ever, reflecting strong sales on Amazon. Speaker 300:08:29Revenue for Q2 also included a full quarter contribution from the newly formed joint venture, DG Converting and Packaging. In the Q2 of 2023, branded product revenue was 22% versus 76% for contract manufacturing revenue. Cost of revenues was 992,000 for the quarter ended June 30, 2023, compared to 460,000 for the quarter ended June 30, 2022. The increase in cost of revenues is primarily aligned with the increase in revenues that would include some costs related to increased marketing efforts that will not be recurring. Gross profit for the Q2 of 2023 was $175,000 compared to a gross profit of $101,000 for the same period in 2022. Speaker 300:09:19Gross profit margin for the Q2 was 15% compared to a gross margin of 18% for the Q2 of 2022. The increase in gross profit was mainly due to a higher level of contract manufacturing sales against fixed costs, partially offset by higher manufacturing labor costs. Total operating expenses, including R and D and SG and A expenses increased to $937,000 for the 3 months ended June 30, 2023, compared to $819,000 for the prior year period. The year over year increase was primarily attributable to increased advertising, marketing and Amazon selling fees, which support our increase in branded revenue as well as higher compensation and benefit expenses. Research and development expenses decreased by $56,000 to $55,000 for the 3 months ended June 30, 2023 from $111,000 for the 3 months ended June 30, 2022. Speaker 300:10:25Net loss for the quarter ended June 30, 2023 improved to $695,000 or $0.12 per basic and diluted share, compared to a net loss of $1,000,000 or $0.19 per basic and diluted share for the same period last year. As of June 30, 2023, Nextel Consolidated had approximately $4,300,000 of of cash and cash equivalents and marketable securities. During the quarter, the company invested in new equipment to increase its capacity at manufacturing facility in anticipation of increased demand in contract manufacturing during the second half of twenty twenty three. As of June 30, 2023, Nextel had 5,696,064 shares of common stock outstanding. I would now like to open the call for questions. Speaker 300:11:17Operator? Operator00:11:19Thank you. We will now begin the question and answer session. There are no questions at this time. This does conclude the question and answer session. And this does conclude today's conference call. Operator00:12:24You may disconnect your lines. Thank you for participating.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallNEXGEL Q2 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) NEXGEL Earnings HeadlinesComparing NEXGEL (NASDAQ:NXGL) and Inari Medical (NASDAQ:NARI)May 4 at 1:41 AM | americanbankingnews.comNEXGEL CEO Adam Levy to Present at Planet MicroCap Showcase 2025April 9, 2025 | msn.comShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.May 7, 2025 | Timothy Sykes (Ad)NEXGEL to Present at the Planet MicroCap Showcase in Las Vegas, NV April 22nd-24thApril 7, 2025 | markets.businessinsider.comNEXGEL Reports Record-Breaking 2024 Financial PerformanceMarch 27, 2025 | msn.comNEXGEL, Inc. (NASDAQ:NXGL) Q4 2024 Earnings Call TranscriptMarch 26, 2025 | insidermonkey.comSee More NEXGEL Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NEXGEL? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NEXGEL and other key companies, straight to your email. Email Address About NEXGELNEXGEL (NASDAQ:NXGL) manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.View NEXGEL ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Stock Eyes Q1 Earnings After UAE UpdatesFord Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostPalantir Stock Drops Despite Stellar Earnings: What's Next?Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Warning or Opportunity After Super Micro Computer's Earnings Upcoming Earnings Coinbase Global (5/8/2025)Monster Beverage (5/8/2025)Brookfield (5/8/2025)Anheuser-Busch InBev SA/NV (5/8/2025)ConocoPhillips (5/8/2025)Cheniere Energy (5/8/2025)McKesson (5/8/2025)Shopify (5/8/2025)Enbridge (5/9/2025)Petróleo Brasileiro S.A. - Petrobras (5/12/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 4 speakers on the call. Operator00:00:00Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to Nextel Incorporated's 2nd Quarter 2023 Earnings Conference Call. I will now turn the call over to Walter Pinto, Managing Director of KCSA Strategic Communications, for introductions. Please go ahead. Speaker 100:00:23Thank you, operator. Good afternoon, and welcome, everyone, to Nextel's Q2 2023 earnings conference call. I'm joined today by Adam Levy, Chief Executive Officer Adam Drabc, Chief Financial Officer of Nextel. Before we begin, I'd like to remind everyone that statements made during today's conference call may be deemed forward looking statements within the meaning of the Safe Harbor of the Private Securities Litigation Reform Act of 1995, and actual results may differ materially due to a variety of risks, uncertainties and other factors. For a detailed discussion of some of the ongoing risks and uncertainties in the company's business, I refer you to the press release issued this evening and filed with the SEC on Form 8 ks as well as the company's reports filed periodically with the SEC. Speaker 100:01:09The company disclaims any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by law. With that, it's my pleasure to turn the call over to Mr. Adam Levy. Adam, please go ahead. Speaker 200:01:26Thank you, Walter, and thank you everyone for joining us today to discuss our Q2 2023 financial and operating results. For the Q2 of 2023, we reported record revenue of $1,170,000 an increase of 108% year over year that exceeded our guidance. This substantial year over year growth reflects sales growth in both our contract manufacturing and branded consumer products. Our contract manufacturing line of business increased 174% year over year, mainly due to the full quarter contribution of our newly formed joint venture CG Converting and Packaging, as well as an increase from our existing core customers. On the branded consumer side, this was our best quarter ever, reflecting strong sales within the Amazon marketplace. Speaker 200:02:16New and existing direct to consumer branded products continued to perform well during the quarter, increasing sales by 44% year over year. Silverseal has become a hero product for us and continues to gain popularity and the reviews are very positive. This product is a unique hydrogel dressing for wounds and burns. These sterile silver patches are FDA cleared and have been clinically shown to kill 99% of staph MRSA and strep. They've also been shown to reduce scarring in wounds. Speaker 200:02:47Silverseal was a behind the counter hospital device for many years and our messaging of hospital grade product now available for home use has resonated well with consumers. In the coming months, we will be seeking to expand Silverseal's distribution into retail and other territories. We've already begun the process to obtain a CE mark as we have interest already from potential partners in Europe. For the Q2, we reported gross profit of 175,000 versus a gross loss of $57,000 in Q1 of 2023. The 2nd quarter included enhanced amounts of promotional materials, customer product samples and other marketing materials to support our new product line launches. Speaker 200:03:31We don't expect these costs to recur in the 3rd Q4. Therefore, we expect our margins to continue to improve in the second half of the year. Our net loss for the quarter was $695,000 down from $814,000 in the Q1 of this year. The improvement in the quarterly loss is attributable to our strong top line growth and the inclusion of a full quarter of CG Converting and Packaging. Our cash and cash equivalent balance, when you include marketable securities, decreased from $5,800,000 as of March 31, 2023 to $4,300,000 at June 30, 2023. Speaker 200:04:11The delta between our improved net loss during the quarter and the net cash decrease period over period was related to an increase in accounts receivables, increased prepaids and other current assets and capital equipment investments. First, the customers of CG Converting and Packaging require lengthier payment terms as their payment terms are closer to 90 days as compared to Nextel's customers who typically receive 30 day payment terms. Therefore, our accounts receivable increased during the quarter by $570,000 to $950,000 total. Prepaids and other current assets increased by $238,000 in the 2nd quarter to $366,000 In 2023, we eliminated the financing of our insurance policies and other higher interest items that we had historically financed, thereby saving the cost of the related interest expense. We also invested an additional $168,000 in property, plant and equipment at Nextel in anticipation of future increased customer demand. Speaker 200:05:16Taking into account the investments we made, we ended the quarter with $4,300,000 in cash, which continues to provide us with sufficient cash runway to operate and invest in accelerating our growth going forward. Our 2nd quarter results were our 1st full quarter with CG Converting and Packaging. We have already begun to realize the benefits of this joint venture. It has contributed materially to our top line growth and is accretive to the bottom line as well. These benefits will only increase once the planned expansion, installation and validation of the new equipment is complete. Speaker 200:05:51Our Q2 results did not include any sales for our new amblyopia patch due to supply chain delays. We have now received all of the materials and we'll be shipping our initial orders this month. We will have early results on adoption in Q3. More recently, in July, we announced a new strategic relationship with Eneta Health, a joint venture company for retail distribution and marketing services in North America. Now that we have fully vetted the audience for our leading products and have gained steady traction in the market, it is time to put these products on shelves. Speaker 200:06:25Enigma's leadership includes Joe Mignaka, an esteemed leader who has served in multiple executive roles, including CEO of Masaz Gandhi, President of Walgreens and President of Duane Reade. It also includes George Lant, a 30 year plus executive with experience in strategic food, drug brokerage sales and marketing. We are excited to leverage the expertise and market presence of Enigma Health's management team to expedite the delivery of our cutting edge hydrogel patches directly to consumers. Joe and George are experts and will be great partners for us. We are actively speaking with many leading retailers and expect to have more news on the progress of our rollout throughout the remainder of the year. Speaker 200:07:07Now halfway through Q3, we are pleased with the trending of our branded products. The sequential growth trend we saw in the first half of the year has continued into the current Q3. We had a very strong July and the 1st 2 weeks of August, and we see continued growth on all of our products on Amazon. We are also continuing to see good sales momentum in contract manufacturing. In closing, we believe in our ability to attract new customers to both Nextel and CG converting and packaging in the second half of twenty twenty three, and we believe that we are well positioned for long term growth. Speaker 200:07:42With that, I would like to turn the call over to our CFO, Adam Drabcic. Adam? Speaker 300:07:48Thank you, Adam. Today, I'll review financial highlights of our Q2 2023 results. For the Q2 of 2023, as Adam mentioned, revenue totaled $1,170,000 an increase of $606,000 or 108 percent, as compared to $561,000 in the Q2 of 2022. This growth was primarily due to sales growth in contract manufacturing of 174% and branded products of 44% year over year. On the branded consumer side, this was our best quarter ever, reflecting strong sales on Amazon. Speaker 300:08:29Revenue for Q2 also included a full quarter contribution from the newly formed joint venture, DG Converting and Packaging. In the Q2 of 2023, branded product revenue was 22% versus 76% for contract manufacturing revenue. Cost of revenues was 992,000 for the quarter ended June 30, 2023, compared to 460,000 for the quarter ended June 30, 2022. The increase in cost of revenues is primarily aligned with the increase in revenues that would include some costs related to increased marketing efforts that will not be recurring. Gross profit for the Q2 of 2023 was $175,000 compared to a gross profit of $101,000 for the same period in 2022. Speaker 300:09:19Gross profit margin for the Q2 was 15% compared to a gross margin of 18% for the Q2 of 2022. The increase in gross profit was mainly due to a higher level of contract manufacturing sales against fixed costs, partially offset by higher manufacturing labor costs. Total operating expenses, including R and D and SG and A expenses increased to $937,000 for the 3 months ended June 30, 2023, compared to $819,000 for the prior year period. The year over year increase was primarily attributable to increased advertising, marketing and Amazon selling fees, which support our increase in branded revenue as well as higher compensation and benefit expenses. Research and development expenses decreased by $56,000 to $55,000 for the 3 months ended June 30, 2023 from $111,000 for the 3 months ended June 30, 2022. Speaker 300:10:25Net loss for the quarter ended June 30, 2023 improved to $695,000 or $0.12 per basic and diluted share, compared to a net loss of $1,000,000 or $0.19 per basic and diluted share for the same period last year. As of June 30, 2023, Nextel Consolidated had approximately $4,300,000 of of cash and cash equivalents and marketable securities. During the quarter, the company invested in new equipment to increase its capacity at manufacturing facility in anticipation of increased demand in contract manufacturing during the second half of twenty twenty three. As of June 30, 2023, Nextel had 5,696,064 shares of common stock outstanding. I would now like to open the call for questions. Speaker 300:11:17Operator? Operator00:11:19Thank you. We will now begin the question and answer session. There are no questions at this time. This does conclude the question and answer session. And this does conclude today's conference call. Operator00:12:24You may disconnect your lines. Thank you for participating.Read morePowered by